Functional RNAs as Drug Targets: Towards Manipulating the RNA Frame-Shifting Element in SARS-CoV2

BBSRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

December 01, 2029
Response Due
Active
Status

Opportunity Overview

Functional RNAs have been recognised over the last two decades as central regulators of biological function, and such RNAs have been shown to directly impact cellular activity. Moreover, functional RNAs play key roles in many diseases, such as cancer, and, finally, many viruses rely on RNAs as well. This centrality means that these molecules are promising therapeutic targets and present an exciting new avenue for drug development.
The pivotal challenge is the structural behaviour of RNAs. In proteins, we generally observe a well-defined structure that can be used for drug development. In contrast, RNAs exhibit multiple structures and shift between them dynamically. Describing RNA structure therefore must consider the entire structural ensemble, which pushes state-of-the-art experimental and computational methods to their limit.
Here, we propose a proof-of-principle study to describe the structural ensemble of the RNA frameshifting element (FSE) from SARS-CoV2, then identify binding pockets across the ensemble, and finally find ligands that impact the functional structural changes of FSE. The FSE has multiple conformations that have been identified as functionally important, allowing for functional interference using ligands binding to the RNA.
The structural ensembles for the FSE wild type and some of its variants and mutants will be  explored using the energy landscape framework, a computational approach that can resolve RNA structural ensembles in detail. One drawback of this methodology currently is the relatively high computational cost. To overcome this shortcoming, a new methodology will be developed based on machine learning to accelerate a crucial step within the framework.
After binding sites and potential ligands are identified based on the RNA structural ensemble, computational and experimental validation will be sought for predicted RNA-ligand binding. On the computational side, this will include analysis of the changes to the structural ensemble...

This is one of 43 active United Kingdom Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyBBSRC
CountryUnited Kingdom
CategoryPharmaceuticals
PublishedDecember 01, 2025
Procurement stageActive solicitation
Response dueDecember 01, 2029
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 10, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Pharmaceutical Wholesale Services
Community Drug and Alcohol Services
Provision of Drug, Alcohol & DNA Testing Services Framework
Personalised Adaptive Medicine
Repurposing Epigenetic Therapy for Hypertrophic Cardiomyopathy to facilitate the innovation and growth of a N.Ireland Cardiac Drug Development Company
Smallpox Vaccine (2026)
Drug and Alcohol Residential Treatment Service - Adults
Intelligent engineering of multicomponent drug crystals

See every United Kingdom Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Pharmaceuticals intelligence report in your inbox

A personalized report on United Kingdom Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.